All Articles
Longevity

Hevolution Foundation Is Backing A New Longevity Startup

April 1, 2024
x min read
Hevolution Foundation Is Backing A New Longevity Startup

The race to build a biotechnology company capable of extending human lifespan is underway.

What’s happening:

  • Hevolution Foundation has announced they have led a $50 million Series A financing round for longevity biotechnology company Aeovian Pharmaceuticals
  • The round also saw notable participation from Apollo Health Ventures, Sofinnova Investments, Evotec and others

The big idea:

  • Aeovian is developing novel therapeutic compounds that target highly selective small molecules to restore cellular metabolic quality
  • The therapeutics compounds being developed by Aeovian are aiming to combat the dysregulated growth and hyperactive signalling that is commonly found in rare genetic disease and age related diseases

Why it matters:

Going deeper:

  • Aeovian Pharmaceuticals has also recently begun dosing patients in their first ever Phase I clinical trial for the treatment of seizures and Tuberous Sclerosis Complex

The intrigue:

Discover the world's most disruptive early stage companies with 35,000+ investors.

The markets and trends that matter, made simple.

Join top talent at the world's most respected institutions, companies, and venture capital funds.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.